The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other emerging markets, Bloomberg News reported.

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Europe’s most expensive stocks aren’t scattered evenly; they’re concentrated in a handful of economic hubs known for their ...

Retail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...